

Immunogenicity of SARS-CoV-2 Vaccine in Dialysis

Authors: Eduardo Lacson, Jr., M.D.,M.P.H.,^{1,2} Christos P. Argyropoulos, M.D.,³ Harold J. Manley, PharmD,² Gideon Aweh, M.S.,² Andrew I. Chin, M.D.,⁴ Loay H. Salman, M.D., M.B.A.,⁵ Caroline M. Hsu, M.D.,¹ Doug S. Johnson, M.D.,² Daniel E. Weiner M.D.¹

Institutions:

¹ Division of Nephrology, Tufts Medical Center, Boston, Massachusetts

² Dialysis Clinic, Inc., Nashville, Tennessee

³ Division of Nephrology, University of New Mexico School of Medicine, Albuquerque, New Mexico

⁴ Division of Nephrology, University of California, Davis School of Medicine, Sacramento, California

⁵ Division of Nephrology, Albany Medical College, Albany, New York

Word Count: 1,197

Abstract Word Count: 250

Key Words:

Dialysis, End Stage Kidney Disease, Chronic Kidney Disease, SARS-CoV-2, COVID-19, Immunization, Vaccine/Vaccination

COI Statement: EL, HJM, GA, DSJ are employees of Dialysis Clinic, Inc. DEW receives funding paid to his institution for his role as Medical Director of Clinical Research for DCI. CPA, AIC, LHS, DEW are medical directors of DCI facilities.

Funding Source: No external funding.

Significance:

In this retrospective observational evaluation of SARS-CoV-2 mRNA vaccine response defined by detectable levels of immunoglobulin-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike antigen of ≥ 2 in serum of patients receiving maintenance dialysis, 165/186 (88.7%) were found to be seropositive (with 70% at maximum titer) at least 14 days after completing the second dose. No significant differences were observed by race or other subgroup or by vaccine manufacturer. Therefore, an equitable and aggressive vaccination strategy for all eligible maintenance dialysis patients, regardless of age, sex, race, ethnicity, or disability, is warranted to prevent the extremely high morbidity and mortality associated with COVID-19 in this high risk population.

Abstract

Background: Patients receiving maintenance dialysis represent a high risk, immune-compromised population with 15-25% COVID mortality rate who were unrepresented in clinical trials evaluated for mRNA vaccines' emergency use authorization.

Method: All patients receiving maintenance dialysis that received two doses of SARS-CoV-2 mRNA vaccines with antibody test results drawn ≥ 14 days after the second dose, as documented in the electronic health record through March 18, 2021 were included. We report seroresponse based on levels of immunoglobulin-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike antigen (seropositive ≥ 2) using FDA-approved semi-quantitative chemiluminescent assay (ADVIA Centaur® XP/XPT COV2G).

Results: Among 186 dialysis patients from 32 clinics in 8 states tested 23 ± 8 days after receiving 2 vaccine doses, mean age was 68 ± 12 years, with 47% women, 21% Black, 26% residents in long-term care facilities and 97% undergoing in-center hemodialysis. Overall seropositive rate was 165/186 (88.7%) with 70% at maximum titer and with no significant difference in seropositivity between BNT162b2/Pfizer (N=148) and mRNA-1273/Moderna (N=18) vaccines (88.1% vs. 94.4%, $p=0.42$). Among patients with COVID-19 history, seropositive rate was 38/38 (100%) with 97% at maximum titer.

Conclusion: Most patients receiving maintenance dialysis were seropositive after two doses of BNT162b2/Pfizer or mRNA-1273/Moderna vaccine. Early evidence suggests that vaccinated dialysis patients with prior COVID-19 develop robust antibody response. These results support an equitable and aggressive vaccination strategy for eligible dialysis patients, regardless of age, sex, race, ethnicity, or disability, to prevent the extremely high morbidity and mortality associated with COVID-19 in this high risk population.

Nearly 550,000 people in the United States (US) receive maintenance dialysis and prevalence estimates approach 3 million worldwide.^{1,2} Patients receiving maintenance dialysis (henceforth “dialysis patients”), particularly those receiving hemodialysis, comprise a population of vulnerable individuals who cannot self-isolate, have a high incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and have Coronavirus Disease 2019 (COVID-19)-associated mortality of 15 to 25%,³⁻⁵ making effective vaccination a priority. Despite this heightened risk and prior reports of diminished response to vaccines versus other viruses such as hepatitis-B and influenza,⁶⁻⁸ the immune response to SARS-CoV-2 vaccination among dialysis patients is unknown due to insufficient trial data. Accordingly, we performed a quality improvement evaluation of multiple Dialysis Clinic, Inc. (DCI) dialysis clinics in the US assessing antibody response following administration of SARS-CoV-2 messenger RNA (mRNA) vaccines.

Methods

Study Setting

DCI implemented a standard clinical protocol for systematic measurement of SARS-CoV-2 spike-antibody immunoglobulin-G (SAb-IgG) that physicians could activate for vaccination in the outpatient dialysis clinic, similar to that for hepatitis-B post-vaccination testing.⁶ As access to the SARS-CoV-2 mRNA vaccines for dialysis patients varied among and within states, they were obtained from nursing homes, hospitals, locally designated centers and pharmacies, and only in few dialysis clinics. Individual physicians ordered post-vaccination SAb-IgG titers based on patient accessibility and clinical interest. All vaccinations were verified and recorded in the DCI electronic health record (EHR). This interim report includes a retrospective evaluation of all patients receiving 2 doses of either BNT162b2/Pfizer or mRNA-1273/Moderna vaccine per manufacturer’s recommendation across 32 DCI clinics in 8 states with SAb-IgG measured ≥ 14 days after the second dose, documented as of March 18, 2021.

SARS-CoV-2 Spike Antibody Assay

DCI Lab measured SAb-IgG against the receptor binding domain (RBD) of the S1 subunit of SARS-CoV-2 spike antigen using US-FDA-approved chemiluminescent assay (ADVIA Centaur® XP/XPT COV2G).^{9, 10} This semi-quantitative assay has a range between 0 and ≥ 20 , with a positive threshold of ≥ 2 . S1-RBD-antibodies are relevant to vaccines incorporating this immune-dominant region to elicit neutralizing (and therefore likely protective) antibodies in vaccinated individuals.¹¹

Electronic Health Record

Vaccination dates, SAb-IgG results, demographic and clinical data including age, sex, race/ethnicity, body mass index, dialysis parameters (i.e. vintage, modality, access, adequacy), albumin, number and types of comorbidities, use of immunomodulatory agents, history of transplantation or COVID-19 diagnosis, and other vaccines administered or hospitalization within 14 days of vaccination were obtained from the DCI-EHR. This retrospective evaluation is a DCI quality improvement evaluation under Western Institutional Review Board (WIRB) exemption. Statistical analyses were performed using SAS v9.4.

Results

Among 186 dialysis patients receiving 2 doses of vaccine, mean age was 68 ± 12 years, with 47% women, 21% Black, 26% residents in long-term care facilities and 97% undergoing in-center hemodialysis (**Table 1**). SAb-IgG was positive (≥ 2) in 165/186 (88.7%) with no significant difference between BNT162b2/Pfizer (N=148) and mRNA-1273/Moderna (N=18) vaccines (88.1% vs. 94.4%, $p=0.42$). The distribution of titer levels drawn over 23 ± 8 days after the 2nd dose is shown in **Figure 1**. Non-responders had mean SAb-IgG titer of 0.4 ± 0.2 vs. 18.2 ± 4.3 among responders ($p < 0.0001$).

Among 148 patients without known COVID-19, 127 (85.8%) were seropositive following vaccination. All 38 patients with COVID-19 diagnosis were seropositive, irrespective of vaccine type, with 37/38 at maximum limit of the assay. In 36 patients, COVID-19 diagnosis occurred 181 ± 118 days prior to completing vaccination. The remaining two patients were long-term care facility residents each exposed to a roommate, and were tested while asymptomatic at 1 and 5 days after their second vaccine dose, respectively (with SAb-IgG titers obtained 20 days and 23 days after vaccination, respectively). Upon review, the latter patient had recent gastrointestinal upset and constipation but neither was hospitalized.

Seroresponse occurred in 73 of 88 women versus 92 of 98 men (83% vs. 94%, $p=0.02$). Results of univariate analysis are indicated in **Table 1**. Non-responders were newer to dialysis and more likely to have other vaccines administered or be hospitalized within 14 days of SARS-CoV-2 vaccination, have potential immunosuppressed state related to immune-modulating drugs, prior transplant, and/or immune-deficiency disorders, and congestive heart failure (CHF). A summary of the clinical characteristics of non-responders is provided in **Table 2**.

Discussion

Among maintenance dialysis patients in the US, 88.7% achieved SAb-IgG >2 , measured ≥ 14 days after two doses of SARS-CoV-2 mRNA vaccine. Near universal seroconversion rates occurred in clinical trials utilized for these vaccines' emergency use authorization, but notably did not include patients on dialysis. Lower seroconversion rate was not unexpected, given the widespread immune dysfunction observed in dialysis-dependent patients. These immune alterations included skewed Th1/Th2 responses, impaired function of the professional antigen presenting cells (APC), and susceptibility of B-cells to apoptosis.¹² The combined deficits in T-cell, APC and B-cell functions render dialysis patients less likely to both seroconvert and maintain

protective titers over time compared to individuals without kidney disease,¹³ previously observed with pneumococcal, hepatitis-B and H1N1 influenza vaccines.^{7,8,14}

Factors associated with poor seroconversion in our cohort include female sex, younger vintage, potential immunosuppression from diseases, transplant or medications, CHF and co-vaccination and hospitalization during the peri-vaccination period. A recent meta-analysis suggests women receiving dialysis respond to vaccines equally to men, although differences in seroconversion rates by sex were noted in some hepatitis-B series.⁷ However, we caution that some of these associations, including that for women, may not be sustained as we accumulate more data. Of note, potential immunosuppressed states and acute hospitalization during the vaccine series have face validity to impact immune response, particularly in the setting of uremic inflammation.^{7,12,15}

Considering the devastating impact of COVID-19 on dialysis patients compared to the potentially dramatic benefit of vaccination on severity of illness,³⁻⁵ it is imperative to explore strategies to monitor and maximize seroconversion. Such knowledge may be useful for patient education and dialogue to reinforce preventive measures. Strategies to improve seroconversion may include additional or higher vaccine doses. Monitoring longitudinal SAb-IgG could inform potential use of booster doses, similar to algorithms used for hepatitis-B vaccination. Such tracking is a component of the quality program at DCI and will be critical in informing the development of alternative vaccination regimens.

A strength of the current report is coverage of multiple areas of the country with a diverse dialysis population. Although limited by small sample size, the data appear sufficient to emphasize that seroconversion should be expected for the majority of maintenance dialysis patients. Additional limitations include an observational design that may have led to residual confounding and selection biases, heavily influenced by accessibility and availability of vaccines. Future studies

could also evaluate T-cell responses given that specific clinical implications of serology tests including the SAb-IgG we utilized, need further elucidation.

In conclusion, the vast majority of maintenance dialysis patients responded with IgG spike antibody titers to a complete series of both SARS-CoV-2 mRNA BNT162b2 and mRNA-1273 vaccines. Further study is needed to determine duration of the seroprotection as well as the ideal approach to non-responders, including whether they should receive a booster dose. Early evidence suggests that vaccinated dialysis patients with prior COVID-19 develop robust antibody response. Our findings support an equitable and aggressive vaccination strategy for all eligible maintenance dialysis patients regardless of age, sex, race, ethnicity, or disability, to prevent the extremely high morbidity and mortality associated with COVID-19 in this high risk population.

Acknowledgment: We are grateful for the assistance from DCI Medical Directors and Clinic Managers caring for our patients who worked to have our patients vaccinated against SARS-CoV-2 and tirelessly documented the information in the EHR. We further thank the nephrologists who have implemented DCI clinical and quality improvement protocols and care recommendations, including the SARS-CoV-2 seroresponse testing algorithm. We also thank Beth Kammer from DCI Laboratories, Vlad Ladik and Brian Tinger from DCI IT-Analytics Department, Karen Majchrzak with DCI Research and Senior/Area Operations Directors who supported this quality improvement project. Dr. Hsu is funded by T32-DK007777.

References:

1. Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. Feb 29 2020;395(10225):709-733.
2. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.
3. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 Infection Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. *American Journal of kidney diseases : the official journal of the National Kidney Foundation*. Jan 16 2021.
4. Sim JJ, Huang CW, Selevan DC, Chung J, Rutkowski MP, Zhou H. COVID-19 and Survival in Maintenance Dialysis. *Kidney Med*. Jan-Feb 2021;3(1):132-135.
5. Couchoud C, Bayer F, Ayav C, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. *Kidney international*. Dec 2020;98(6):1519-1529.
6. Chi, C, Patel, P, Pilishvilli T, et al. Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. CDC; December, 2012:1-12 [Updated Vaccine Guideline for Dialysis and Chronic Kidney Disease Patients \(cdc.gov\)](#) Last Accessed March 26, 2021.
7. Udomkarnjananun S, Takkavatakarn K, Praditpornsilpa K, et al. Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis. *Journal of Nephrology*. Apr 2020;33(2):343-354.
8. Crespo M, Collado S, Mir M, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. *Clinical Journal of the American Society of Nephrology*: Sep 2011;6(9):2208-2214.
9. <https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/sars-cov-2-igg-assay> - Manufacturer website accessed March 22, 2021.
10. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas> - FDA website accessed March 22, 2021.
11. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 586, 589–593 (2020).
12. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. *Clinical Journal of the American Society of Nephrology*: Sep 2008;3(5):1526-33.
13. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. *American Journal of Kidney Diseases*: 2005 Dec;46(6):997-1011.
14. Vandecasteele SJ, De Bacquer D, Caluwe R, et al. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study. *Clin Microbiol Infect*. 2018 Jan;24(1):65-71.
15. Bergström J, Lindholm B, Lacson E Jr, et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? *Semin Dial*. 2000 May-Jun;13(3):163-75.

Figure Legend

Figure 1. Distribution of spike antibody IgG titers for SARS-CoV-2 mRNA vaccinated maintenance dialysis patients (N=186) drawn over 23 ± 8 days after the second dose.

Table 1. Patient characteristics presented as mean \pm standard deviation or number (percent).

Demographics	All Patients (N=186)	Responders (N=165)	Non-Responders (N=21)
Age (years)	67.9 \pm 12.2	67.7 \pm 12.4	70.0 \pm 10.7
\geq 65 years	123 (66.1)	107 (64.8)	16 (76.2)
Female	88 (47.3)	73 (44.2)	15 (71.4)^a
Race			
White	73 (39.3)	62 (37.6)	11 (52.4)
Black	39 (21.0)	36 (21.8)	3 (14.3)
Native American	33 (17.7)	31 (18.8)	2 (9.5)
Asian/Pacific Islander	19 (10.2)	18 (10.9)	1 (4.8)
Other/Unknown	22 (11.8)	18 (10.9)	4 (19.1)
Hispanic	15 (8.1)	14 (8.5)	1 (4.8)
Vintage (months)	58.1 \pm 54.3	60.6 \pm 54.2	38.7 \pm 52.2^a
Body Mass Index (kg/m²)	28.7 \pm 7.1	28.7 \pm 6.9	29.2 \pm 8.8
Long Term Care Facility	48 (25.8)	41 (24.9)	7 (33.3)
Home Dialysis	6 (3.2)	5 (3.0)	1 (4.8)
Dialysis Access			
Fistula	129 (69.4)	117 (70.9)	12 (60.0)
Graft	29 (15.6)	26 (15.8)	3 (15.0)
Central Venous Catheter	23 (12.4)	18 (10.9)	5 (25.0)
Peritoneal Dialysis Catheter	5 (2.7)	4 (2.4)	1 (4.8)
Adequate Dialysis Dose^c	174 (93.6)	155 (93.9)	19 (90.5)
Serum Albumin (g/dl)	3.8 \pm 0.4	3.8 \pm 0.4	3.5 \pm 0.6

Other Vaccines within 14 days	20 (10.8)	15 (9.1)	5 (23.8)^a
Pneumonia	4 (2.2)	3 (1.8)	1 (4.8)
Hepatitis B	17 (9.1)	13 (7.9)	4 (19.1)
Potential Immunosuppression	30 (18.2)	30 (18.2)	8 (38.1)^a
Immune-modulating Meds	29 (15.6)	23 (13.9)	6 (28.6)
Prior Transplant	10 (5.4)	8 (4.9)	2 (9.5)
Immunodeficiency Disorder	10 (5.4)	6 (3.6)	4 (19.1)
Hospitalization within 14 days	34 (18.3)	24 (14.6)	10 (47.6)^b
Disability^d	17 (9.1)	17 (10.3)	0 (0.0)
Tobacco Use	22 (11.8)	21 (12.7)	1 (4.8)
Alcohol Abuse Disorder	14 (7.5)	14 (8.5)	0 (0.0)
Drug Abuse Disorder	8 (4.3)	6 (3.6)	2 (9.5)
COVID-19 History	38 (20.4)	38 (23.0)	0 (0.0)^a
Number of Comorbidities	3.2 ± 1.9	3.2 ± 1.9	3.6 ± 1.7
Diabetes Mellitus	129 (69.4)	113 (68.5)	16 (76.2)
Hypertension	152 (81.7)	134 (81.2)	18 (85.7)
Congestive Heart Failure	37 (19.9)	27 (16.4)	10 (47.6)^b
COPD ^e	34 (18.3)	30 (18.2)	4 (19.1)
Stroke/Cerebrovascular Disorder	23 (12.4)	19 (11.5)	4 (19.1)
Peripheral Vascular Disease	25 (13.4)	22 (13.3)	3 (14.3)
Thyroid Disorder	36 (19.4)	30(18.2)	6 (28.6)
History of Cancer	18 (9.7)	14 (8.5)	4 (19.1)

^a P-value <0.05; ^b P-value <0.01; ^c Adequate dialysis defined by hemodialysis dose $spKt/V \geq 1.2$ or peritoneal dialysis dose weekly $Kt/V \geq 1.7$; ^d Amputee, wheelchair use or inability to perform activities of daily living; ^e COPD=Chronic Obstructive Pulmonary Disease. Note: Comparisons between responders with non-responders utilized Chi-Square or Analysis of Variance for categorical variables and T-test / Kruskal-Wallis/Mann-Whitney test for normal/non-normally distributed continuous variables.

Table 2. Detailed summary of characteristics of SARS-CoV-2 mRNA vaccine non-responders.

Patient	Age Range	Sex	Race	Ethnicity	Notable Comorbidity	Prescribed Medications Impacting Immune Function	Clinical Event within 14 days of COVID Vaccination	
							Hospitalization	Other Vaccine
1	65-69	F	Native American	Non-Hispanic	DM	None	Yes	Heplisav
2	65-69	F	Native American	Non-Hispanic	DM, seizure disorder, CVA, PVD, Depression calciphylaxis	None	None	None
3	80-84	F	White	Hispanic	DM, A fib, CHF, hypothyroid	None	Yes	None
4	80-84	M	Unknown	Non-Hispanic	DM, A fib, CHF, hypothyroid, COPD	None	Yes	None
5	75-79	F	Black	Non-Hispanic	SLE, prior Transplant, SVC syndrome	hydroxychloroquine, prednisone	None	None
6	55-59	F	White	Non-Hispanic	Thyrotoxicosis, Bipolar Disorder, Depression	None	None	None
7	50-54	F	White	Non-Hispanic	HIV, Bipolar Disorder, Illicit drug use, Cervical CA history	lamivudine, dolutegravir, ritonavir, darunavir	None	None
8	70-74	F	White	Non-Hispanic	DM, Gout, Osteoarthritis, prior Transplant	prednisone, tacrolimus	None	Engerix
9	70-74	F	Asian	Non-Hispanic	CHF, SLE, Hepatitis B, Osteoarthritis, Colon CA history	prednisone, mycophenolate, hydroxychloroquine, entecavir	None	None
10	45-49	F	Black	Unknown	DM, CHF, Hepatitis B, PVD,	None	Yes	None
11	70-74	M	Unknown	Unknown	DM, GERD, prior Transplant	prednisone, tacrolimus, mycophenolate, thymoglobulin ^c	Yes	Prevnar
12 ^a	70-74	M	White	Non-Hispanic	DM, A fib, Depression	None	None	None
13	50-54	F	White	Non-Hispanic	DM, CHF, hypothyroid	None	None	None
14	80-84	F	White	Non-Hispanic	DM, CHF, CAD, hypothyroid, Gout, Depression	None	Yes	None

15	70-74	F	White	Unknown	DM, Depression, COPD	None	Yes	None
16	65-69	F	Unknown	Unknown	DM, CHF, Lyme disease, Depression, Osteoarthritis, Gout, Uterine CA history	None	None	None
17 ^b	75-79	M	Black	Non-Hispanic	DM, CHF, DVT, BPH, GERD, Gout	None	Yes	Heplisav
18	65-69	F	Unknown	Non-Hispanic	DM	None	Yes	None
19	75-79	M	White	Non-Hispanic	DM, hypothyroid, gout, neuropathy, Melanoma CA history,	None	Yes	Heplisav
20	80-84	M	White	Non-Hispanic	DM, A fib, CHF, COPD, Gout	hydroxychloroquine	Yes	None
21	60-64	F	White	Unknown	A fib, CHF, Breast CA history	None	Yes	None

^a Received Moderna vaccine, all else received Pfizer vaccine; ^b Peritoneal dialysis modality, all else utilized hemodialysis; ^c Communicated by nephrologist.

Figure 1

